SURFACTANT REPLACEMENT THERAPY - 05/09/11
Résumé |
High-permeability edema of the lung, once called albuminous expectoration, was described over a century ago by Pinault, occurring in a setting we would now identify as re-expansion pulmonary edema.43 Ashbaugh et al3 provided the first medical description of such edema occurring in association with trauma, pancreatitis, drug ingestion, aspiration, or lung infection. These investigators, studying fluid from the minced lungs of two patients, noted that it reduced surface tension on a Wilhelmy balance to 24 and 21 dynes/cm2—more than twice the value they considered normal. These early observations, made at a time when the surfactant system of the lung was largely a theoretical consideration, prompted the conclusion that surfactant “loss is associated with the development of the clinical, physiologic, and pathological conditions” in patients with acute respiratory distress syndrome (ARDS).
Since these prescient observations, critical components of lung surfactant have been identified, and alterations in the levels of those components in the setting of the acute respiratory ARDS have been described. Animal models of ARDS have been developed that reflect the alterations seen in human disease, and results of treatment with exogenous surfactant suggest benefit derived from that intervention. Infants with respiratory distress syndrome have been shown to share certain pathologic features with ARDS patients and to benefit from surfactant therapy. Finally, limited clinical experience suggests that patients with ARDS may benefit from treatment with exogenous surfactant. This article presents considerations pertinent to surfactant treatment of patients with ARDS and reviews current relevant investigations.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to Roger G. Spragg, MD, San Diego VA Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, e-mail: rspragg@ucsd.edu Supported in part by grant HL23584-20 from the National Institutes of Health, Bethesda, MD. Financial Disclosure: Roger G. Spragg, MD, is a paid consultant to Byk Gulden Pharmaceuticals. |
Vol 21 - N° 3
P. 531-541 - septembre 2000 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
